Product details

About this product

25 mg Pen | Retatrutide | Triple-Receptor Agonist Compound Retatrutide is a peptide designed to activate three metabolic hormone receptors: GLP-1 + GIP + Glucagon These pathways are involved in appetite, food intake, blood-glucose regulation and energy metabolism. What is Retatrutide Being Studied For? Retatrutide is being investigated primarily for obesity, overweight and related metabolic conditions. Retatrutide have demonstrated substantial reductions in body weight. Potential Effects Being Investigated Clinical research on retatrutide has demonstrated effects including: • Reduced appetite and food intake • Significant body-weight reduction • Improved blood-glucose control • Improvements in several cardiometabolic measurements • Effects on obesity-related health conditions Doses Studied in Clinical Trials Participants began at: Weeks 1–4 — 2 mg once weekly Depending on the assigned target dose, clinical-trial escalation then occurred every four weeks: Weeks 5–8 — 4 mg once weekly Weeks 9–12 — 6 mg once weekly Weeks 13–16 — 9 mg once weekly Always consult your coach or consultant before taking any dose. Important Product Information Brand product: REVIVA+ Product: Retatrutide Pen Total content: 25 mg Compound: Retatrutide The 25 mg printed on the REVIVA+ pen refers to its labelled product content and should not be interpreted as a 25 mg weekly dose.